Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study
Abstract Background and Objectives Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have become an important therapeutic option for patients with dyslipidemia. Evolocumab and alirocumab are monoclonal antibodies targeting circulating PCSK9, whereas inclisiran is a small interfering R...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2026-05-01
|
| Serier: | BMC Cardiovascular Disorders |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s12872-026-05931-5 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|